Mitarbeiter des Rudolf-Boehm-Institutes
Therapeutic siRNA: State-of-the-Art and Future Perspectives | SpringerLink
Curriculum vitae
Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson's D
Vorlage Geschäftsbrief mit Siegel
Accommodation – CAS in Radiopharmaceutical Chemistry/Radiopharmacy | ETH Zurich
Programme – CAS in Radiopharmaceutical Chemistry/Radiopharmacy | ETH Zurich
Zeitschrift für Naturforschung C
Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects | Scientific Reports
SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC) | Scientific Reports
Nanoparticle-complexed antimiRs for inhibiting tumor growth and metastasis in prostate carcinoma and melanoma
Multiple effects of the special ATâ•'rich binding protein 1 (SATB1) in colon carcinoma
Mitarbeiter des Rudolf-Boehm-Institutes
Front Cover: Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors (ChemMedChem 9/2022) - Schäker‐Hübner - 2022 - ChemMedChem - Wiley Online Library
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells
Mitarbeiter des Rudolf-Boehm-Institutes
Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy
Loop | Achim Aigner
European Technology Platform on Nanomedicine
Analysis of Transcriptional Regulation of the Human miR-17-92 Cluster; Evidence for Involvement of Pim-1
Achim Aigner | Leipzig University, Germany | Pharmaceutica 2017 | Conferenceseries
